Navigation Links
CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
Date:2/21/2008

evation Acute Coronary Syndrome; Poster, Monday, March 31, 2008, 3:00 p.m. CST

Efficacy and Safety of Ranolazine in Chronic Angina: Observations from the Randomized, Double-blind, Placebo-controlled MERLIN-TIMI 36 Trial; Poster, Tuesday, April 1, 2008, 11:00 a.m. CST

Regadenoson

Heart Rate Response to Adenosine and Regadenoson in Diabetes Mellitus: A Marker of Autonomic Cardiac Neuropathy; Poster, Tuesday, April 1, 2008, 11:30 a.m. CST

Additional information regarding the ACC 57th Annual Scientific Sessions can be accessed at http://acc08.acc.org/Pages/default.aspx.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT- 6883, which is being developed for potential treatment of cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking sta
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LOUIS , July 29, 2014  Sigma-Aldrich Corporation ... water and energy use, increased its investment in Green ... service around the world last year, the Company announced ... What if Science Changed the World? ... earned several honors for being a responsible corporate citizen, ...
(Date:7/29/2014)... 2014 G-CON Manufacturing Inc., the standard ... announced a new leadership appointment designed to drive the ... abroad. , Maik Jornitz, Chief Operating Officer of ... charged with leading the pioneering company through its next ... stage of development and look forward to providing our ...
(Date:7/29/2014)... 2014 Dr. Jason Wendel – recipient of ... one of the Top 10 Plastic Surgeon Specialists for Nashville, ... products. His complete line includes a Hydration Booster, Retexturing Night ... face and skin a younger, more radiant appearance while protecting ... is different, that is why at Dr. J. J. Wendel ...
(Date:7/28/2014)... light, developed by researchers at the University of Cambridge, ... the realm of science fiction, such as invisibility cloaks ... be a reality for quite some time, the technique ... blocks a few billionths of a metre across can ... through them, and works on large chunks all at ...
Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Dr. J. J. Wendel Launches New Line of Skin Care Products 2Building 'invisible' materials with light 2
... Products with Herculex(R) XTRA Will Qualify for ... Lower Crop Insurance Rates, ... plant Pioneer(R) brand corn hybrids with the Herculex(R) XTRA,trait, including those ... crop insurance premium reductions in select states in 2009., DuPont ...
... has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo ... activity of selected AstraZeneca compounds. , ... EXTON, ... represents a significant opportunity for Melior to deliver value to AstraZeneca ...
... Product Developed from the VisEn-Merck & Co., Inc. ... Fluorescence Molecular Imaging Agent,Portfolio and Broadens Applications in ... BEDFORD, Mass., Aug. 19 VisEn Medical, ... research through medicine, announced,today the commercial launch of ...
Cached Biology Technology:DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products 2DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products 3VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent 2
(Date:7/29/2014)... 29, 2014 Research and Markets  has ... Intelligence (BI) Market 2014-2018" report to their offering. ... The term BI refers to applications and technologies ... analyzing information about a company,s operations. BI help organizations ... business; for example, metrics on sales, production, and internal ...
(Date:7/29/2014)... to the edge of science, Clment Vidal takes on ... and the End: Does our universe have a beginning ... alone in the universe? What is the role of ... science and committed to philosophical rigor, the book presents ... is not an accident, but may well be the ...
(Date:7/29/2014)... UK overseas territory of Ascension Island, one of the ... a renaissance. , Writing in the journal Biodiversity ... and Ascension Island Government Conservation Department report that the ... Atlantic outpost has increased by more than 500 per ... as 24,000 nests are now estimated to be laid ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Book: 'The Beginning and the End' 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... peak in sight fitness peak, that is for ... Lenski, MSU Hannah Distinguished Professor of Microbiology and Molecular Genetics, ... generating more than 50,000 generations. In a paper published in ... author and MSU graduate student in Lenski,s lab, compares it ...
... genetic signature of respiratory syncytial virus (RSV), the leading cause ... key step toward a better understanding of the immune response ... and a tool that could allow physicians to determine the ... from a team at The Research Institute at Nationwide Children,s ...
... may be more able to cope with dry conditions ... and Colorado State University used a computer model to ... the Amazon rainforest may be more able to withstand ... climate models. Many climate models over predict the ...
Cached Biology News:No peak in sight for evolving bacteria 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 3Amazon rainforest more able to withstand drought than previously thought 2
... StabilZyme SELECT Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a saline ... a combination of 0.02% methylisothiazolone and 0.02% ... Stabilizer is a diluent and stabilizer for ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
... Stabilizer is a bovine protein-free alternative to ... aqueous solution that contains non-toxic chemicals in ... 6.6 - 7.2, and does not contain ... activity of antibodies and other biomolecules that ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
Biology Products: